237 related articles for article (PubMed ID: 15758699)
1. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?
Carroll PR
J Urol; 2005 Apr; 173(4):1061-2. PubMed ID: 15758699
[No Abstract] [Full Text] [Related]
2. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].
Bastian PJ; Stief CG
MMW Fortschr Med; 2010 May; 152(19):36. PubMed ID: 20556999
[No Abstract] [Full Text] [Related]
4. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
Ito K
Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
[No Abstract] [Full Text] [Related]
5. Application of prostate-specific antigen in prostate cancer.
Liang SL
MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
[No Abstract] [Full Text] [Related]
6. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer--the snowball is rolling.
Ruutu M; Salo J; Nordling S; Rannikko S
Ann Chir Gynaecol; 1999; 88(1):5-8. PubMed ID: 10230675
[No Abstract] [Full Text] [Related]
8. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
9. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
10. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
Egawa S
Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
[No Abstract] [Full Text] [Related]
11. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
12. [Elevated PSA--what to do?].
Machemer H; Rohde D
MMW Fortschr Med; 2008 Oct; 150(44):38-9. PubMed ID: 19024490
[No Abstract] [Full Text] [Related]
13. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
14. Revisiting my personal decision about prostate-specific antigen testing in 2005.
Barry MJ
BJU Int; 2005 Nov; 96(7):954-6. PubMed ID: 16225507
[No Abstract] [Full Text] [Related]
15. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
16. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
18. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
Richard F
Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
[No Abstract] [Full Text] [Related]
19. AUA issues a policy report on PSA monitoring. The American Urological Association.
Scott Morey S
Am Fam Physician; 2000 Aug; 62(4):883-4. PubMed ID: 10969861
[No Abstract] [Full Text] [Related]
20. [Mass screening for prostate cancer in Nagano].
Ishizuka O; Satoh T; Kobayashi S; Nishizawa O
Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
